Lipocine (LPCN) Tops Q2 EPS by 12c
Tweet
Share
E-mailGet Alerts LPCN Hot Sheet
Join SI Premium – FREE
Lipocine (NASDAQ: LPCN) reported Q2 EPS of ($0.32), $0.12 better than the analyst estimate of ($0.44). Revenue for the quarter came in at $190 million versus the consensus estimate of $162.5 thousand.
For earnings history and earnings-related data on Lipocine (LPCN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- eXp World Holdings, Inc. (AGNT) Misses Q2 EPS by 9c; offers guidance
- Cumberland Pharmaceuticals (CPIX) Reports Q2 Loss of $0.20
- Light & Wonder, Inc. (LNWO) Tops Q2 EPS by 71c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
